Fatigue in patients with metastatic breast cancer undergoing single-agent taxane-based chemotherapy: a real-world data global network.

Background

Cancer-related fatigue (CRF) occurs in nearly all patients with metastatic breast cancer (MBC).

Objectives

This real-world analysis aimed to describe the prevalence and importance of fatigue in patients with MBC within 3 months of treatment with single-agent taxane-based chemotherapy during the timeframe of 2020-2022 in the United States and Europe. It was also conducted to assess whether there was a difference in relapsed patients compared to patients diagnosed

Design

Electronic health records were analyzed from approximately 150 million patients to identify patients with MBC who underwent taxane treatment.

Results

In 2021, 50,490 patients had MBC, of whom 16,170 were diagnosed

Conclusion

At least one in four patients with MBC undergoing taxane-based treatment will experience fatigue. This highlights the importance of validating screening tools to identify CRF, which is necessary to advance clinical trials aimed at investigating treatment strategies to improve patient-centered outcomes for fatigue.

Informations de copyright

© The Author(s), 2024.

Déclaration de conflit d'intérêts

AF is a consultant for Dompé Farmaceutici S.p.A, participant on advisory boards for Roche, Novartis, Lilly, Pfizer, MSD, Pierre Fabre, Eisai, Epionpharma, Gilead, Seagen, Astra Zeneca, and Exact Science. EMG, RW, MCS, EB, MD, PAR, and MA are employees of Dompé Farmaceutici S.p.A. The other authors have no conflicts of interest to declare.